Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 4Gynecologic 1

Conditions

Ovarian Neoplasms 4Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Uterine Neoplasms 1Turcot syndrome 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Gynecologic Cancers 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Filgrastim 15Carboplatin 10Ifosfamide 9Doxorubicin 9Cyclophosphamide 9Peripheral Blood Stem Cell Transplantation 7pembrolizumab 6Radiotherapy 6Gemcitabine 6Temozolomide 5Etoposide 5Cisplatin 5Paclitaxel 4Docetaxel 4Amifostine 4aldesleukin 3aflibercept 3Trastuzumab 3Specimen Handling 3Radiosurgery 3Psychiatric Rehabilitation 3Magnetic Resonance Spectroscopy 3Biopsy 3tislelizumab 2sodium thiosulfate 2selinexor 2pazopanib 2palbociclib 2etoposide phosphate 2eribulin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × Immune Checkpoint Inhibitors × Gynecologic × Clear all
NCT04239443 2020-01-27

Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer

Hunan Cancer Hospital

Phase 2 Unknown
120 enrolled
GynecologicSarcoma

Sarcoma, Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡